Dr. Lin Wang, MD, PhD

Dr. Wang practices at California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD in San Francisco, California.

Dr. Wang's NPI, 1710412085, was assigned on April 25, 2017. Dr. Wang graduated from Tulane School of Medicine in 2017. Dr. Wang holds California license A159290.

Dr. Wang's primary practice is California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD, at 2333 Buchanan St, San Francisco, CA 94115.

Dr. Wang's primary practice is California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD in San Francisco, California. Dr. Wang is also affiliated with California Pacific Medical Center Van Ness Campus. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Wang to 3 more hospitals, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wang practices, 9 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Wang's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Wang is board certified in hematology by the American Board of Internal Medicine. Dr. Wang is licensed in California.

CMS data shows 45 Medicare services from Dr. Wang across 2 procedure codes in 2024, all of them office visits, for 43 Medicare patients. Medicare paid $8,443 for them. Every service was in an office.

CMS counts 43 Medicare patients who saw Dr. Wang in 2024. The largest group is 65 to 74, with 20 patients. 72% of them have high cholesterol, and 67% have high blood pressure. 30% are also on Medicaid. Their average risk score is 0.99, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wang's median patient age at 64, with 59% women.

In 2024, Dr. Wang wrote 58 Medicare Part D claims for 17 patients. 78% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $218 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Wang for performance year 2024, reported as part of a group. Dr. Wang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wang as offering telehealth.

Dmand AI links 11 papers to Dr. Wang, published from 2011 to 2021. 2021 was the busiest year, with 2. The most frequent topics are Brain Neoplasms, Cell Proliferation and Glioblastoma. Dr. Wang has published most often in Bioinformatics. Dr. Wang's most frequent co-authors are Susan M. Chang, MD, Manish Kumar Aghi, MD, PhD and Nduka Mgbechinyere Amankulor, MD.

CMS Open Payments shows 74 general payments to Dr. Wang from 32 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 54% of the total. Genentech, Inc. paid the most, $1,933.

Dr. Wang graduated from Tulane School of Medicine in 2017.

Dr. Wang is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.